Weight Regulation Affecting Patents (Class 514/4.8)
-
Patent number: 8853154Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: GrantFiled: September 12, 2013Date of Patent: October 7, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Hui Wei, Aaron P. Yamniuk, Vidhyashankar Ramamurthy, Alexander T. Kozhich, Martin J. Corbett, Stanley Richard Krystek, Jr.
-
Patent number: 8853153Abstract: An agent for suppressing elevation of blood GIP concentration and an agent for preventing or improving obesity, each of which contains a polyglutamic acid as an active ingredient.Type: GrantFiled: July 16, 2010Date of Patent: October 7, 2014Assignee: Kao CorporationInventors: Kotomi Ishimaru, Kazuhisa Sawada, Akira Shimotoyodome
-
Publication number: 20140296131Abstract: The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration.Type: ApplicationFiled: June 9, 2014Publication date: October 2, 2014Applicant: NOVO NORDISK A/SInventors: Jane Spetzler, Lauge Schaeffer, Jesper Lau, Janos T. Kodra, Kjeld Madsen, Patrick W. Garibay, Jacob Kofoed, Steffen Reedtz-Runge, Henning Thoegersen, Ingrid Pettersson
-
Publication number: 20140296139Abstract: MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.Type: ApplicationFiled: March 14, 2014Publication date: October 2, 2014Inventors: Pinchas COHEN, Changhan LEE, Laura J. COBB
-
Publication number: 20140287001Abstract: This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Inventor: Kunwar Shailubhai
-
Publication number: 20140287002Abstract: This invention provides novel guanylate cyclase C (GC-C) agonists and their therapeutic use. The agonists may be used either alone or in combination with one or more additional agents.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Inventor: Kunwar Shailubhai
-
Publication number: 20140271586Abstract: The present disclosure relates to nutritional compositions including a protein equivalent source that includes a peptide component comprising selected peptides. The protein equivalent source may further include intact protein, hydrolyzed protein, including partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of promoting healthy body weight in a target subject by stimulating adiponectin levels by providing the nutritional compositions disclosed herein to a target subject, which includes a pediatric subject.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: Mead Johnson Nutrition (Asia Pacific) Pte. Ltd.Inventors: DIRK HONDMANN, ERIC A.F. VAN TOL, GABRIELE GROSS, MARIEKE H. SCHOEMAKER, TEARTSE TIM LAMBERS
-
Publication number: 20140271555Abstract: The present disclosure provides a method for activating adiponectin by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce risk of heart attack and help in maintaining healthy weight. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: MEAD JOHNSON NUTRITION (ASIA PACIFIC) PTE. LTD.Inventor: MEAD JOHNSON NUTRITION (ASIA PACIFIC) PTE. LTD
-
Publication number: 20140256620Abstract: The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.Type: ApplicationFiled: May 22, 2014Publication date: September 11, 2014Applicant: Cornell Research Foundation, Inc.Inventors: Hazel H. Szeto, Shaoyl Liu, Sunghee Cho
-
Publication number: 20140249075Abstract: The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.Type: ApplicationFiled: November 8, 2013Publication date: September 4, 2014Applicant: Cornell Research Foundation, Inc.Inventors: Hazel H. Szeto, Shaoyl Liu, Sunghee Cho
-
Publication number: 20140249076Abstract: Provided herein are amylin-calcitonin peptide conjugates having enhanced duration of biological activity, and methods of use thereof. The amylin-calcitonin peptide conjugates include duration enhancing moieties, such as water soluble polymers and long chain aliphatic groups, bound to the amylin-calcitonin peptide. Methods of use are provided for treatment of an eating disorder, insulin resistance, obesity, overweight, abnormal postprandial hyperglycemia, Type I diabetes, Type II diabetes, gestational diabetes, metabolic syndrome, dumping syndrome, hypertension, dyslipidemia, cardiovascular disease, hyperlipidemia, sleep apnea, cancer, pulmonary hypertension, cholescystitis or osteoarthritis.Type: ApplicationFiled: October 17, 2012Publication date: September 4, 2014Inventors: Manoj P. Samant, Ved Srivastava, Odile Esther Levy, Christine M. Mack, William E. Rote
-
Patent number: 8822411Abstract: The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of modulating an effect of myostatin on a cell by contacting the cell with an agent that affects myostatin signal transduction in the cell. In addition, the invention provides a method of ameliorating the severity of a pathologic condition, which is characterized, at least in part, by an abnormal amount, development or metabolic activity of muscle or adipose tissue in a subject, by modulating myostatin signal transduction in a muscle cell or an adipose tissue cell in the subject.Type: GrantFiled: August 23, 2010Date of Patent: September 2, 2014Assignee: The Johns Hopkins University School of MedicineInventors: Se-Jin Lee, Alexandra C. McPherron
-
Publication number: 20140243259Abstract: The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-?2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of increasing skeletal muscle mass, and methods of bringing about a weight reduction or reduction in obesity. Also provided are pharmaceutical compositions for use thereof.Type: ApplicationFiled: May 15, 2014Publication date: August 28, 2014Applicant: ASTON UNIVERSITYInventors: Michael J. Tisdale, Steven Russell
-
Publication number: 20140243258Abstract: Methods and compositions are presented for use in diagnostic, imaging or targeting of therapeutic agents to treat obesity/adiposity-associated disorders, where such as compositions and methods identify and use peptides to selectively target adipose tissue stromal cells in mammals, both in vitro and in vivo.Type: ApplicationFiled: March 30, 2012Publication date: August 28, 2014Applicant: The Board of Regents of the University of Texas SystemInventors: Mikhail G. Kolonin, Alexes Daquinag, Yan Zhang
-
Publication number: 20140242089Abstract: A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a Zn-?2-glycoprotein, or of a fragment thereof having an apparent molecular mass Mr greater than 6.0 kDa as determined by gel exclusion chromatography. Methods of isolation and purification from biological material are also disclosed together with uses of the material for making up pharmaceutical compositions, especially pharmaceutical compositions useful for treating mammals to achieve weight reduction or for controlling obesity. In addition, uses of the material for developing diagnostic agents and for identifying inhibitors of lipolytic activity for therapeutic purposes are disclosed.Type: ApplicationFiled: May 13, 2014Publication date: August 28, 2014Inventors: Michael J. Tisdale, Penio T. Totorov
-
Publication number: 20140234405Abstract: To date, no immune tolerance agent or combination of immune tolerance agents has been able to sustain insulin-independence among type 1 diabetes patients. This patent provides methods and pharmaceutical compositions for providing insulin independence among newly diagnosed and existing type 1 diabetes. Methods include utilization of PPIs, which increase gastrin resulting in the transformation of human ductal tissue into insulin-secreting new beta cells, used in combination with an immune tolerance agent to protect the new insulin-producing beta cells generated by the PPI from immune destruction. Compositions and methods are provided for beta cell generation therapy comprising at least one member from a group of PPIs with formulations selected from immune tolerance agents, when used in combination result in insulin-independence among new and existing type 1 patients whom currently require insulin to sustain life.Type: ApplicationFiled: February 15, 2013Publication date: August 21, 2014Inventor: Claresa Levetan
-
Publication number: 20140235534Abstract: The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-?2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as ? adrenergin receptor agonists, ? adrenergin receptor antagonists, and/or glycemic control agents.Type: ApplicationFiled: April 30, 2014Publication date: August 21, 2014Applicant: ASTON UNIVERSITYInventors: Michael J. Tisdale, Steven Russell
-
Publication number: 20140228282Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.Type: ApplicationFiled: April 23, 2014Publication date: August 14, 2014Applicant: Eli Lilly and CompanyInventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
-
Publication number: 20140221271Abstract: Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO: 1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed.Type: ApplicationFiled: June 5, 2012Publication date: August 7, 2014Inventors: Shawn P Iadonato, Eric J Tarcha
-
Publication number: 20140221279Abstract: Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors.Type: ApplicationFiled: April 14, 2014Publication date: August 7, 2014Applicant: Children's Hospital Medical CenterInventors: Christopher L. Karp, Senad Divanovic, Jessica L. Allen
-
Publication number: 20140221278Abstract: Provided are methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. Also provided are specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.Type: ApplicationFiled: February 5, 2013Publication date: August 7, 2014Inventor: Yitzchak Hillman
-
Publication number: 20140212407Abstract: The present disclosure relates to the treatment, e.g. reduction, of body fat mass levels for example in overweight and obese subjects. The present disclosure also relates to weight control in a subject where obesity should be avoided. Disclosed herein are methods of reducing body fat mass e.g. reducing obesity or preventing weight gain and agents used in such methods whereby the agents inhibit a sulphur containing amino acid. Also included in the present disclosure include, without being limited to, methods for determining regimes for the treatment of obesity as well as other subject matter.Type: ApplicationFiled: September 5, 2013Publication date: July 31, 2014Applicant: Isis Innovation LimitedInventors: Amany ELSHORBAGY, Helga Margareta REFSUM
-
Publication number: 20140213510Abstract: The present invention discloses the protein pleitrophin secreted by the developing pancreas, and polynucleotides, which identify and encode this protein. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome.Type: ApplicationFiled: February 22, 2013Publication date: July 31, 2014Inventors: Daria ONICHTCHOUK, Ulrike BURK
-
Publication number: 20140213511Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.Type: ApplicationFiled: January 27, 2014Publication date: July 31, 2014Inventors: Hugo Matern, Darrin Anthony Lindhout, Raj Haldankar
-
Publication number: 20140213512Abstract: Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided.Type: ApplicationFiled: August 30, 2012Publication date: July 31, 2014Applicant: Amgen Inc.Inventors: Murielle Marie Ellison, Shanaka Stanislaus, Jing Xu
-
Publication number: 20140205600Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.Type: ApplicationFiled: January 24, 2014Publication date: July 24, 2014Applicant: ACCELERON PHARMA INC.Inventors: John Knopf, Jasbir Seehra
-
Patent number: 8785128Abstract: Disclosed are methods of identifying a genetic variant in a person determined to have or be predisposed having a fatty liver by determining whether the person has PNPLA3-I148M. Also disclosed are methods of identifying a genetic variant in a person by determining whether the person has PNPLA3-I148M; and prescribing to the person a treatment to reduce liver fat or associated inflammation.Type: GrantFiled: November 26, 2012Date of Patent: July 22, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Helen H Hobbs, Jonathan C Cohen
-
Publication number: 20140194352Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.Type: ApplicationFiled: November 26, 2013Publication date: July 10, 2014Applicant: NGM Biopharmaceuticals, Inc.Inventors: Lei Ling, Darrin Anthony Lindhout
-
Patent number: 8772229Abstract: The invention provides inhibitors of ghrelin O-acyltransferase, and methods of making and using them. In some embodiments, the invention provides bisubstrate analog inhibitors of ghrelin O-acyltransferase, which can be effective in treating, for example, obesity and diabetes mellitus.Type: GrantFiled: September 18, 2009Date of Patent: July 8, 2014Assignee: The Johns Hopkins UniversityInventors: Philip A. Cole, Bradley P. Barnett, Yousang Hwang, Jef D. Boeke
-
Publication number: 20140187474Abstract: A therapeutic formulation containing mucin glycans derived from one or a number of nutritionally appropriate sources is described.Type: ApplicationFiled: March 6, 2014Publication date: July 3, 2014Inventor: Justin L. Sonnenburg
-
Publication number: 20140187470Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer), a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder) by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.Type: ApplicationFiled: January 2, 2014Publication date: July 3, 2014Inventors: Gary S. Jacob, Kunwar Shailubhai
-
Publication number: 20140187479Abstract: Novel compounds, particularly derivatives of boroarginine, boroornithine and borolysine that selectively modulate, regulate, and/or inhibit enteropeptidase. Compositions, particularly pharmaceutical compositions, as well as methods to treat excess weight, obesity and diseases associated with an abnormal fat metabolism.Type: ApplicationFiled: December 16, 2013Publication date: July 3, 2014Inventors: Itzik Harosh, Sandrine Braud, Marco A. Ciufolini
-
Publication number: 20140187480Abstract: The invention relates to the use of specifically designed lipid component with optimal fatty acid profile, an enhanced portion of the palmitic acid residues in the sn-2 position and present as lipid globules with a phospholipid coating for an early in life diet for improving the development of a healthy body composition, in particular prevention of obesity, later in life.Type: ApplicationFiled: June 18, 2012Publication date: July 3, 2014Inventors: Eline Marleen Van Der Beek, Marieke Abrahamse-Berkeveld, Annemarie Oosting, Martine Sandra Alles
-
Patent number: 8759282Abstract: A film comprising as a film-forming agent an alginate salt of monovalent cation or a mixture of alginate salts containing at least one alginate salt of monovalent cation, the film-forming agent being such that a 10% aqueous solution thereof at a temperature of 20° C. has a viscosity of 100-1000 mPas, as measured at a shear rate of 20 rpm by use of a Brookfield viscometer with a spindle No. 2. A method of preparing the film. The film is useful for delivery of active ingredients to a mammal.Type: GrantFiled: December 22, 2006Date of Patent: June 24, 2014Assignee: Uppsalagruppen Medical ABInventors: Kjell G Stenberg, Fredrik Hubinette
-
Publication number: 20140171361Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.Type: ApplicationFiled: February 19, 2014Publication date: June 19, 2014Applicant: Salk Institute for Biological StudiesInventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jaemyoung Suh
-
Publication number: 20140170107Abstract: Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors.Type: ApplicationFiled: February 12, 2014Publication date: June 19, 2014Applicant: Children's Hospital Medical CenterInventors: Christopher L. Karp, Senad Divanovic, Jessica L. Allen
-
Patent number: 8754037Abstract: Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.Type: GrantFiled: December 21, 2011Date of Patent: June 17, 2014Assignee: Hanall Biopharma Co., Ltd.Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
-
Publication number: 20140162944Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b) 20-80 wt. % of at least one phosphatidyl choline (PC); c) 5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) up to 20 wt. % polar solvent e) at least one peptide active agent; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.Type: ApplicationFiled: May 25, 2012Publication date: June 12, 2014Applicant: CAMURUS ABInventors: Fredrik Tiberg, Catalin Nistor, Markus Johnsson
-
Publication number: 20140162943Abstract: The disclosure provides N-terminus conformationally constrained compounds, which may comprise peptide mimetics and/or amino acid substitutions, which may be used in peptides, such as GLP-1 receptor agonist compounds, to induce ?-turn secondary structure at the N-terminus. The N-terminus conformationally constrained compounds may be used for research purposes; to produce GLP-1 receptor agonist compounds having improved GLP-1 receptor binding activity, enzymatic stability, or in vivo glucose lowering activity; and to develop GLP-1 receptor agonist compounds which have fewer amino acid residues. The disclosure also provides GLP-1 receptor agonist compounds, such as exendins, exendin analogs, GLP-1(7-37), GLP-1(7-37) analogs, comprising the N-terminus conformationally constrained compounds. The compounds are useful for treating various diseases, such as diabetes and obesity. The disclosure also provides methods for chemically synthesizing the N-terminus conformationally constrained compounds.Type: ApplicationFiled: January 28, 2014Publication date: June 12, 2014Applicants: ASTRAZENECA PHARMACEUTICALS, LP, AMYLIN PHARMACEUTICALS, LLCInventors: Josue ALFARO-LOPEZ, Abhinandini SHARMA, Soumitra S. GHOSH
-
Patent number: 8748375Abstract: Methods for affecting body composition include the use of amylin agonists, such as pramlintide or davalintide. Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.Type: GrantFiled: March 17, 2010Date of Patent: June 10, 2014Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Christine M. Mack, Jonathan David Roth
-
Publication number: 20140154181Abstract: The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radioimaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for targeted chemotherapy.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: STEBA BIOTECH S.A.Inventors: Doron EREN, Tamar YECHEZKEL, Yoseph SALITRA, Natalia KOUDINOVA
-
Publication number: 20140155315Abstract: The invention provides a synthetic polypeptide of Formula I? (SEQ ID NO: 1): X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13??I or an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.Type: ApplicationFiled: November 18, 2013Publication date: June 5, 2014Applicant: NOVARTIS AGInventors: Frédéric Zecri, Kayo Yasoshima, Philipp Grosche, Jun Yuan, Hongjuan Zhao
-
Publication number: 20140155316Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: February 10, 2014Publication date: June 5, 2014Applicants: New York University, Salk Institute for Biological StudiesInventors: Moosa Mohammadi, Regina M. Goetz, Ronald M. Evans, Michael Downes, Jae Myoung Suh
-
Patent number: 8741835Abstract: A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, H-Inp-D-Bal-D-Trp-Phe-Apc-NH2 (SEQ ID NO:73) or other suitable ghrelin agonist, to counteract the catabolic effects of dexamethasone and other natural glucocorticoids.Type: GrantFiled: November 2, 2011Date of Patent: June 3, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Giovanni Tulipano, Andrea Giustina, Zheng Xin Dong, Michael DeWitt Culler
-
Publication number: 20140148382Abstract: The present invention is directed to peptide compositions and methods of using the peptide compositions to treat prediabetes, diabetes, obesity, high blood pressure and metabolic syndrome.Type: ApplicationFiled: November 22, 2013Publication date: May 29, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Yuqing E. Chen, Changyong Xue, Jifeng Zhang
-
Patent number: 8735347Abstract: Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors.Type: GrantFiled: February 2, 2012Date of Patent: May 27, 2014Assignee: Children's Hospital Medical CenterInventors: Christopher L. Karp, Senad Divanovic, Jessica L. Allen
-
Publication number: 20140142022Abstract: The invention provides a synthetic polypeptide of Formula I?: or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Inventors: Frederic ZECRI, Andrei GOLOSOV, Philipp GROSCHE, Kayo YASOSHIMA, Hongjuan ZHAO, Qi-Ying HU, Hidetomo IMASE, David Thomas PARKER
-
Publication number: 20140142023Abstract: The invention is directed to a pharmaceutical composition comprising at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. The invention is also directed to a pharmaceutical composition comprising at least one FGF-21 (fibroblast growth factor 21) compound, at least one DPP-4 (dipeptidyl peptidase-4) inhibitor and optionally GLP-1R (glucagon-like peptide-1 receptor) agonist and/or at least one at least one anti-diabetic drug for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.Type: ApplicationFiled: June 29, 2012Publication date: May 22, 2014Applicant: SANOFIInventors: Mark Sommerfeld, Hans-Ludwig Schaefer, Oliver Boscheinen, Paul Habermann, Ercole Rao, Matthias Dreyer
-
Publication number: 20140128318Abstract: The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.Type: ApplicationFiled: June 7, 2012Publication date: May 8, 2014Applicant: Hanmi Science Co., Ltd.Inventors: Sung Youb Jung, Myung Hyun Jang, Ling Ai Shen, Young Kyung Park, Young Jin Park, Se Chang Kwon
-
Publication number: 20140120097Abstract: The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue.Type: ApplicationFiled: October 26, 2012Publication date: May 1, 2014Inventor: Claresa Levetan